<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02613481</url>
  </required_header>
  <id_info>
    <org_study_id>YDA-001</org_study_id>
    <nct_id>NCT02613481</nct_id>
  </id_info>
  <brief_title>The Emotional and Functional Benefits of Poly-L-Lactic Acid</brief_title>
  <official_title>The Emotional and Functional Benefits of Poly-L-Lactic Acid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yardley Dermatology Associates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Galderma Laboratories, L.P.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Yardley Dermatology Associates</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluates the emotional and functional benefits of Poly-L-Lactic Acid
      (Sculptra™), a cosmetic product used to fill defects of the skin. All participants will
      receive Sculptra™.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Facial volume loss can result in emotional distress and functional impairment in some
      affected individuals. Poly-L-Lactic Acid (Sculptra™) stimulates collagen production in the
      skin thereby replenishing some of the collagen lost to natural aging and ultraviolet damage.
      This study will assess the emotional and functional benefits of Poly-L-Lactic Acid treated
      subject's through self report measurement tools.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">August 1, 2017</completion_date>
  <primary_completion_date type="Actual">June 1, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Subject Self Reported Quality of Life Scale</measure>
    <time_frame>3 months post initial injection</time_frame>
    <description>Self report Likert Scale Title: Facial Volume Restoration Outcome Questionnaire 35 Questions 1-7 rating with higher score meaning a worse outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Rosenberg Self-Esteem Scale</measure>
    <time_frame>3 months post initial injection</time_frame>
    <description>Self reported self esteem measure Title: Rosenberg Self-Esteem Scale Scale of 1-4, scale design with higher score relating to worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Rosenberg Self-Esteem Scale</measure>
    <time_frame>6 months post initial injection</time_frame>
    <description>Self reported self esteem measure Title: Rosenberg Self-Esteem Scale Scale of 1-4, scale design with higher score relating to worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Subject Self Reported Quality of Life Scale</measure>
    <time_frame>6 months post initial injection</time_frame>
    <description>Self report Likert Scale Title: Facial Volume Restoration Outcome Questionnaire 35 Questions 1-7 rating with higher score meaning a worse outcome</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Facial Volume Loss</condition>
  <arm_group>
    <arm_group_label>Poly-L-Lactic Acid (Sculptra) injection</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Poly-L-Lactic Acid (Sculptra) injection for all enrolled subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Poly-L-Lactic Acid (Sculptra) injection</intervention_name>
    <description>1 vial of of poly-l-lactic acid (Sculptra) reconstituted in the usual sterile fashion with 7cc of sterile water and 2cc of Lidocaine without epinephrine. The contents of the vial will be injected as deemed appropriate by the certified injector and agreed upon by the study subject.</description>
    <arm_group_label>Poly-L-Lactic Acid (Sculptra) injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must be an outpatient, male or female subjects of any race, 35 years of age or
             older.

          2. Subject must have any degree of facial volume loss.

          3. Subjects of all Fitzpatrick skin types are eligible.

          4. Subject must be able to follow study instructions and likely to complete all required
             visits, as assessed by the Investigator.

          5. Subject must sign an IRB-approved Informed Consent form, Photographic Release Form,
             and the Authorization for Use and release of Health and Research Study Information
             (HIPAA) form prior to any study-related procedures being performed.

        Exclusion Criteria:

          1. Any of the previous facial treatments:

             c. Any facial filler in the past 2 years d. Prior injection of permanent facial
             implant

          2. Have any skin pathology or condition that could interfere with the evaluation of the
             face.

          3. Be unable to communicate or cooperate with the Investigator due to a language barrier
             (non-English speaking), poor mental development, or impaired cerebral function.

          4. Have evidence of alcohol or drug abuse (Investigator opinion), or history of poor
             cooperation, non-compliance with medical treatment, or unreliability.

          5. Have used an investigational device, biologic or drug in the past 30 days, or be
             currently participating in an experimental drug, biologic or device trial.

          6. Have a condition or be in a situation that, in the Investigator's opinion, may put the
             subject at significant risk, may confound the study results, or may interfere
             significantly with the subject's participation in the study.

          7. Be an employee (or a relative of an employee) of the Investigator, Sponsor or
             representative of the Sponsor.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://yardleyderm.com//</url>
    <description>Click here for more information about this study: The Emotional and Functional Benefits of Poly-L-Lactic Acid</description>
  </link>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>October 29, 2015</study_first_submitted>
  <study_first_submitted_qc>November 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2015</study_first_posted>
  <results_first_submitted>January 9, 2019</results_first_submitted>
  <results_first_submitted_qc>May 7, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 29, 2019</results_first_posted>
  <last_update_submitted>May 7, 2019</last_update_submitted>
  <last_update_submitted_qc>May 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 21, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT02613481/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Poly-L-Lactic Acid (Sculptra) Injection</title>
          <description>Poly-L-Lactic Acid (Sculptra) injection for all enrolled subjects
Poly-L-Lactic Acid (Sculptra) injection: 1 vial of of poly-l-lactic acid (Sculptra) reconstituted in the usual sterile fashion with 7cc of sterile water and 2cc of Lidocaine without epinephrine. The contents of the vial will be injected as deemed appropriate by the certified injector and agreed upon by the study subject.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Poly-L-Lactic Acid (Sculptra) Injection</title>
          <description>Poly-L-Lactic Acid (Sculptra) injection for all enrolled subjects
Poly-L-Lactic Acid (Sculptra) injection: 1 vial of of poly-l-lactic acid (Sculptra) reconstituted in the usual sterile fashion with 7cc of sterile water and 2cc of Lidocaine without epinephrine. The contents of the vial will be injected as deemed appropriate by the certified injector and agreed upon by the study subject.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Ethnicity</title>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian or Alaskan</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hawaiian or Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Subject Self Reported Quality of Life Scale</title>
        <description>Self report Likert Scale Title: Facial Volume Restoration Outcome Questionnaire 35 Questions 1-7 rating with higher score meaning a worse outcome</description>
        <time_frame>3 months post initial injection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Poly-L-Lactic Acid (Sculptra) Injection</title>
            <description>Poly-L-Lactic Acid (Sculptra) injection for all enrolled subjects
Poly-L-Lactic Acid (Sculptra) injection: 1 vial of of poly-l-lactic acid (Sculptra) reconstituted in the usual sterile fashion with 7cc of sterile water and 2cc of Lidocaine without epinephrine. The contents of the vial will be injected as deemed appropriate by the certified injector and agreed upon by the study subject.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Subject Self Reported Quality of Life Scale</title>
          <description>Self report Likert Scale Title: Facial Volume Restoration Outcome Questionnaire 35 Questions 1-7 rating with higher score meaning a worse outcome</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.45" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Rosenberg Self-Esteem Scale</title>
        <description>Self reported self esteem measure Title: Rosenberg Self-Esteem Scale Scale of 1-4, scale design with higher score relating to worse outcome.</description>
        <time_frame>3 months post initial injection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Poly-L-Lactic Acid (Sculptra) Injection</title>
            <description>Poly-L-Lactic Acid (Sculptra) injection for all enrolled subjects
Poly-L-Lactic Acid (Sculptra) injection: 1 vial of of poly-l-lactic acid (Sculptra) reconstituted in the usual sterile fashion with 7cc of sterile water and 2cc of Lidocaine without epinephrine. The contents of the vial will be injected as deemed appropriate by the certified injector and agreed upon by the study subject.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Rosenberg Self-Esteem Scale</title>
          <description>Self reported self esteem measure Title: Rosenberg Self-Esteem Scale Scale of 1-4, scale design with higher score relating to worse outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.56" spread=".93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Rosenberg Self-Esteem Scale</title>
        <description>Self reported self esteem measure Title: Rosenberg Self-Esteem Scale Scale of 1-4, scale design with higher score relating to worse outcome.</description>
        <time_frame>6 months post initial injection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Poly-L-Lactic Acid (Sculptra) Injection</title>
            <description>Poly-L-Lactic Acid (Sculptra) injection for all enrolled subjects
Poly-L-Lactic Acid (Sculptra) injection: 1 vial of of poly-l-lactic acid (Sculptra) reconstituted in the usual sterile fashion with 7cc of sterile water and 2cc of Lidocaine without epinephrine. The contents of the vial will be injected as deemed appropriate by the certified injector and agreed upon by the study subject.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Rosenberg Self-Esteem Scale</title>
          <description>Self reported self esteem measure Title: Rosenberg Self-Esteem Scale Scale of 1-4, scale design with higher score relating to worse outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.24" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Subject Self Reported Quality of Life Scale</title>
        <description>Self report Likert Scale Title: Facial Volume Restoration Outcome Questionnaire 35 Questions 1-7 rating with higher score meaning a worse outcome</description>
        <time_frame>6 months post initial injection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Poly-L-Lactic Acid (Sculptra) Injection</title>
            <description>Poly-L-Lactic Acid (Sculptra) injection for all enrolled subjects
Poly-L-Lactic Acid (Sculptra) injection: 1 vial of of poly-l-lactic acid (Sculptra) reconstituted in the usual sterile fashion with 7cc of sterile water and 2cc of Lidocaine without epinephrine. The contents of the vial will be injected as deemed appropriate by the certified injector and agreed upon by the study subject.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Subject Self Reported Quality of Life Scale</title>
          <description>Self report Likert Scale Title: Facial Volume Restoration Outcome Questionnaire 35 Questions 1-7 rating with higher score meaning a worse outcome</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.22" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>9 Months</time_frame>
      <desc>Subject population of decreased facial volume not due to concomitant disease state is not considered at higher risk for mortality than age matched general population. In additional Poly-L -Lactic Acid has not been associated with any increased risk of mortality.</desc>
      <group_list>
        <group group_id="E1">
          <title>Poly-L-Lactic Acid (Sculptra) Injection</title>
          <description>Poly-L-Lactic Acid (Sculptra) injection for all enrolled subjects
Poly-L-Lactic Acid (Sculptra) injection: 1 vial of of poly-l-lactic acid (Sculptra) reconstituted in the usual sterile fashion with 7cc of sterile water and 2cc of Lidocaine without epinephrine. The contents of the vial will be injected as deemed appropriate by the certified injector and agreed upon by the study subject.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain/Discomfort</sub_title>
                <description>expected post procedure pain/discomfort</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Trials</name_or_title>
      <organization>Yardley Dermatology Associates, PC</organization>
      <phone>2155796155</phone>
      <email>rfried@yardleyderm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

